Recent developments include ongoing clinical trial results, regulatory milestones, insider stock transactions, analyst coverage, and institutional share sales, reflecting active market and operational activity.

• Mineralys reported that lorundrostat reduced heart failure risk biomarkers in hypertension trials, supporting its clinical profile [N4].
• The FDA accepted the NDA for lorundrostat in hypertension with a PDUFA target action date of December 22, 2026 [N1].
• An insider banked a $557,000 options gain ahead of the December FDA decision, indicating insider activity [N2].
• A $350,000 insider sale occurred ahead of the FDA decision, reflecting insider stock transactions [N3].
• Velan Capital sold 140,000 shares worth $4.1 million, indicating institutional share disposal [N5].
• TD Cowen initiated coverage of Mineralys Therapeutics with a buy recommendation, reflecting analyst interest [N7].
• The company released its Q1 2026 earnings transcript detailing financial and operational updates [N6].
• The Q4 2025 earnings call transcript provided insights into recent clinical and business progress [N8].

Lorundrostat's demonstrated clinical efficacy in reducing systolic blood pressure in patients with uncontrolled and resistant hypertension, combined with a favorable safety and tolerability profile, supports its potential as an innovative treatment option. The FDA's acceptance of the NDA and the scheduled PDUFA date provide a regulatory milestone. The company's strong liquidity position supports ongoing development and potential commercialization efforts. Additional clinical data in comorbid conditions such as CKD and OSA may expand the therapeutic indications. Positive analyst coverage and insider transactions indicate market interest and confidence in the company's prospects.

The company faces significant risks including the need to successfully obtain FDA approval for lorundrostat, which remains uncertain until the PDUFA decision. The substantial net losses and reliance on external financing, including a loan secured by intellectual property, pose financial risks. Potential breaches of loan covenants or inability to generate sufficient product revenue could lead to default and asset foreclosure. Clinical trial results in some comorbid indications have shown mixed outcomes. Competition from other therapies and challenges in market adoption may limit commercial success. Insider sales and institutional share disposals may reflect caution among some stakeholders.

Mineralys Therapeutics' moat is based on its proprietary, highly selective aldosterone synthase inhibitor, lorundrostat, which targets a significant unmet need in uncontrolled and resistant hypertension driven by dysregulated aldosterone. The compound's selectivity, favorable safety profile, and once-daily dosing differentiate it from existing mineralocorticoid receptor antagonists that have side effects limiting their use. The company's clinical trial program, including pivotal Phase 3 studies and additional trials in comorbid conditions, supports the potential clinical utility of lorundrostat. The FDA acceptance of the NDA and the company's intellectual property rights secured under loan agreements further contribute to its competitive position. However, the biopharmaceutical industry is highly competitive and subject to regulatory and clinical risks.

• Regulatory Approval Risk: The FDA's decision on the NDA for lorundrostat is pending with a target date in December 2026. Approval is not guaranteed and regulatory feedback or requests could delay or prevent commercialization.
• Financial and Indebtedness Risk: The company has significant net losses and relies on a loan agreement secured by its assets, including intellectual property. Failure to comply with covenants or generate sufficient revenue could lead to default and foreclosure.
• Clinical Development Risk: While pivotal trials showed positive results, some trials in comorbid conditions have mixed outcomes. Long-term safety and efficacy data are still being collected.
• Market and Competitive Risk: Existing therapies and new entrants in hypertension and related conditions may compete with lorundrostat. Market adoption depends on physician acceptance and payer coverage.

• Mineralys Therapeutics, Inc. is a biopharmaceutical company focused on developing medicines targeting diseases driven by dysregulated aldosterone, primarily hypertension and related cardiorenal conditions such as chronic kidney disease (CKD) and obstructive sleep apnea (OSA).
• The company's lead product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor (ASI) designed to reduce aldosterone levels by inhibiting the CYP11B2 enzyme.
• Lorundrostat is being developed for treatment of uncontrolled hypertension (uHTN) and resistant hypertension (rHTN), conditions affecting a significant portion of hypertensive patients who do not achieve blood pressure goals with existing therapies.
• Lorundrostat has completed six clinical trials including Phase 3 pivotal trials Launch-HTN and Phase 2 Advance-HTN, demonstrating statistically significant and clinically meaningful reductions in systolic blood pressure with a favorable safety profile.
• The FDA accepted the New Drug Application (NDA) for lorundrostat in December 2025 with a Prescription Drug User Fee Act (PDUFA) target action date of December 22, 2026.
• Additional clinical trials include Explore-CKD and Explore-OSA, investigating lorundrostat's effects in patients with hypertension and comorbid CKD or OSA, showing clinically meaningful blood pressure reductions and safety.
• Lorundrostat has a pharmacokinetic half-life of 10 to 12 hours, supporting once-daily dosing, and has shown low incidence of hyperkalemia and no cortisol suppression or adrenal insufficiency.
• The company licensed lorundrostat from Tanabe Pharma Corporation, which conducted early development including Phase 1 trials.
• Hypertension is a widespread condition with over 120 million patients in the U.S., many of whom have uncontrolled blood pressure despite treatment; dysregulated aldosterone is a key factor in approximately 30% of these patients.
• Current standard-of-care treatments include multiple drug classes, but many patients require multiple agents and still fail to reach blood pressure targets; mineralocorticoid receptor antagonists (MRAs) have side effects limiting their use.
• Lorundrostat's mechanism of inhibiting aldosterone synthesis is considered a preferable approach to MRAs that block aldosterone action but do not reduce its production.
• The company reported cash and cash equivalents of $138.3 million and short-term investments of $523.1 million as of June 30, 2026, with a current ratio of 34.46 and cash ratio of 34.24, indicating strong liquidity.
• Net loss for the six months ended June 30, 2026, was $241.1 million with basic and diluted EPS of -$2.85 per share.
• The company entered into a Loan Agreement in June 2026, which includes customary covenants and a security interest in substantially all assets, including intellectual property, with risks related to indebtedness and covenant compliance disclosed.
• Recent news highlights include positive clinical trial results, FDA acceptance of NDA, insider stock transactions ahead of the December 2026 FDA decision, analyst coverage initiation, and share sales by institutional investors.
• The company is conducting an ongoing open-label extension trial (Transform-HTN) to collect long-term efficacy and safety data for lorundrostat.
• The company faces risks related to its indebtedness, including potential default and foreclosure on assets, and the need to generate sufficient product revenue to service debt and fund operations.
• The company has disclosed detailed clinical trial results, regulatory milestones, and financial condition in its 10-K and 10-Q filings as of March 12, 2026, and August 11, 2026, respectively.